Turn Therapeutics 于 2025 年 10 月 14 日在纳斯达克首次亮相时任命资深顾问 Arthur Golden 为董事会成员。 Turn Therapeutics appointed veteran advisor Arthur Golden to its board on its Nasdaq debut, October 14, 2025.

转基因治疗师已任命阿瑟·金(Arthur Golden)担任董事会董事,他是具有40年法律和治理经验的资深公司顾问。 Turn Therapeutics has appointed Arthur Golden, a veteran corporate advisor with four decades of experience in law and governance, to its board of directors. 该公司于2025年10月14日开始在纳斯达克交易,正在推进治疗湿疹和形肌病的晚期临床计划,并为其配方获得三项FDA许可. The company, which began trading on Nasdaq on October 14, 2025, is advancing late-stage clinical programs for eczema and onychomycosis, building on three FDA clearances for its formulations. 公司治理,监管合规和战略增长方面的专业知识加强了Turn的领导地位,因为它开发了耐热的疫苗输送系统,并扩大了皮肤病和伤口护理管道. Golden’s expertise in corporate governance, regulatory compliance, and strategic growth strengthens Turn’s leadership as it develops thermostable vaccine delivery systems and expands its dermatology and wound care pipeline.